🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

PHIO PHIO

Company Profile ↓
$1.07
-54.85% 1Y
Mkt Cap$12.43M
P/E-0.74
P/B0.62
52W High$2.48
52W Low$0.86
Book Value$1.73
EPS (TTM)$-1.45

Company Overview

PHIO (PHIO) is a publicly traded company listed on with a market capitalization of $12.43M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Growth & Price Performance

Stock Price Performance

1 Year:-54.85%
6 Months:+9.30%
3 Months:-5.31%
1 Month:+5.94%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 13% of range
$0.86 $2.48
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)53.80 · Neutral
Price Performance
1M+5.94%
3M-5.31%
6M+9.30%
1Y-54.85%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 56.9% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.74
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$1.73
Price to Book
0.62
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-45.76%
ROE
-43.17%
ROA
-40.48%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.34
EPS (TTM)
$-1.45

Balance Sheet & Liquidity

Debt/Equity
0.00
Quick Ratio
-
Current Ratio
16.03
Debt
$0
Total Assets
$17.41M
Current Assets
$17.40M
Working Capital
$20.14M

Ownership

Promoter Holding
1.93%
Chg in Prom Hold
0.00%
FII / Inst Holding
10.81%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
$-9.22M
Free Cash Flow
$-7.99M
Operating Cash Flow
$-7.98M
Shares Outstanding
11.62M
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 92.00K29.00K--34.00K--10.00K9.00K--0023.00K58.00K57.00K21.00K00000-------------00000
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------1.87M2.31M2.50M2.53M4.17M
Operating Income -2.07M-2.29M-2.02M-2.21M-2.95M-2.17M-2.50M-2.25M-2.21M-2.22M-7.08M-2.51M-2.48M-2.24M-1.90M-1.49M-2.15M-2.06M-2.11M-2.36M-1.67M-2.31M-3.64M-2.68M-3.74M-2.64M-2.52M-3.57M-3.60M-2.55M-2.78M-2.21M-1.91M-1.59M--1.87M-2.31M-2.50M-2.53M-4.17M
EBITDA ------------------------------------1.87M-2.31M-2.50M-2.53M-4.17M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------1.77M-2.17M-2.39M-2.37M-4.00M
Tax Provision ----------------------------------------
Net Income -2.06M-2.28M-2.01M-2.21M-2.94M-2.17M-2.50M-2.23M-2.21M-2.21M-5.46M-2.51M-2.48M-2.24M-1.90M-1.49M-2.12M-2.04M-2.09M-2.35M-1.67M-2.31M-3.41M-2.69M-3.74M-2.64M-2.53M-3.58M-3.60M-2.55M-2.78M-2.15M-1.85M-1.52M--1.77M-2.17M-2.39M-2.37M-4.00M
Diluted EPS -----------------------0.32-0.20-0.28-2.34-2.22-3.14-3.15-13.27-10.25-0.47-3.62-1.54--0.41-0.45-0.44--0.34
R&D Expense 1.23M1.48M1.18M1.46M2.11M1.36M1.73M1.30M1.34M1.46M1.35M1.33M1.49M1.36M1.18M838.00K1.09M1.15M1.04M1.22M779.00K1.26M2.43M1.56M2.67M1.59M1.30M2.51M2.13M1.38M1.81M1.15M866.00K644.00K-886.00K1.07M1.18M-2.79M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------97.00K399.00K-34.00K19.00K15.00K138.00K21.00K0-0000
Cost of Revenue -----------------------
Gross Profit -----------------------
Operating Expenses -------------------11.46M10.70M7.39M9.22M
Operating Income ---------12.77M-12.97M-20.95M-8.83M-10.24M-9.02M-14.06M-7.36M-8.99M-8.79M--11.46M-10.70M-7.39M-9.22M
EBITDA --------------------11.27M-10.51M-7.35M-9.22M
Interest Expense -----------------------
Pretax Income --------------------11.48M-10.83M-7.15M-8.70M
Tax Provision ------------------00---
Net Income -89.00K-3.27M-2.21M-2.40M-10.99M-14.37M-18.39M-11.99M-2.54M-12.88M-20.93M-8.80M-10.22M-8.99M-12.45M-7.36M-8.91M-8.79M--11.48M-10.83M-7.15M-8.70M
Diluted EPS --------------------90.86-46.76-9.08-1.45
R&D Expense --------6.62M10.45M17.65M5.68M6.92M5.42M5.37M4.33M4.30M3.72M8.89M7.01M6.33M3.64M4.62M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --------1.69M5.59M14.94M9.19M11.16M13.40M4.10M15.32M8.04M15.74M-12.81M9.36M5.74M21.49M
Current Assets -------------------12.45M9.32M5.74M21.48M
Cash & Equivalents --------503.00K5.13M11.39M8.50M5.12M12.91M3.58M----11.78M8.49M5.38M21.03M
Inventory -----------------------
Receivables -----------------------
Total Liabilities --------2.28M1.71M2.08M----1.74M2.29M2.72M-1.98M1.63M1.01M1.34M
Current Liabilities --------1.78M1.68M2.08M1.33M2.27M2.54M2.27M1.74M1.88M2.20M-1.94M1.63M1.01M1.34M
Long Term Debt ----------------0231.00K-----
Total Debt ------------------295.00K170.00K35.00K0-
Total Equity -89.00K-968.00K-450.00K2.00K10.82M8.97M741.00K2.43M-587.00K-5.84M4.94M2.75M8.89M10.86M1.83M13.58M5.75M13.02M-10.84M7.73M4.72M20.15M
Shares Outstanding -------------------126.56K416.37K1.73M11.62M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -5.06M-6.31M----9.51M-7.52M-8.64M-8.80M--12.13M-10.75M-7.11M-7.98M
Investing Cash Flow 16.00K-3.09M----103.00K-5.00K-72.00K-19.00K--121.00K-5.00K8.00K-12.00K
Financing Cash Flow 9.67M15.67M---292.00K18.82M772.00K16.13M--26.00K7.41M4.00M23.64M
Capital Expenditure -15.00K-78.00K-95.00K-57.00K-4.00K-203.00K-5.00K-72.00K-19.00K--121.00K-5.00K-1.00K-12.00K
Free Cash Flow -5.08M-6.39M----9.72M-7.53M-8.72M-8.82M--12.25M-10.75M-7.11M-7.99M
Net Change in Cash -----------12.28M-3.34M-3.11M15.65M

Ratios (Annual)

Figures in %.

Metric Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------------
Operating Margin % ----------13,376.3%-5,250.4%--30,108.8%-47,447.4%-93,746.7%-5,336.2%-42,795.2%------
Net Margin % ----------13,278.4%-5,244.4%--30,067.6%-47,336.8%-83,013.3%-5,333.3%-42,419.0%------
ROE % 100.0%338.0%490.9%-120,250.0%-101.5%-160.3%-2,481.4%-493.5%432.2%220.5%-423.4%-320.6%-115.0%-82.9%-679.3%-54.2%-155.0%-67.6%--105.9%-140.1%-151.4%-43.2%
ROCE % --------15,573.2%-331.6%-162.9%-112.4%-115.2%-83.0%-767.2%-54.2%-145.9%-64.9%--105.4%-138.4%-156.4%-45.8%

Shareholding Pattern

Insiders
1.93%
Institutions
10.81%
Public Float
11.03%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PHIO

Yahoo Finance Wed, 22 Jul 2026

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti…

Yahoo Finance Wed, 22 Jul 2026

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeut…

Yahoo Finance ue, 21 Jul 2026

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Brings extensive experience in patient care, dermatologic research and commercializationKing of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical …

Yahoo Finance Wed, 15 Jul 2026

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones

Phio Pharmaceuticals has strengthened the intellectual property protection surrounding its INTASYL® gene silencing platform after receiving multiple favorable patent decisions across the United States, Canada, and Japan. Key Investor Takeaw…

Yahoo Finance Wed, 15 Jul 2026

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Securing additional patent protection in the United States, Canada, and Japan for INTASYL CompoundsKing of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biophar…

Yahoo Finance Fri, 26 Jun 2026

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available…

PHIO — Frequently Asked Questions

What is the current share price of PHIO?

As of 2026-08-05 17:25 PDT, PHIO trades at $1.07 on NASDAQ/NYSE. Its 52-week range is $0.86 to $2.48.

What is the market capitalisation of PHIO?

PHIO has a market capitalisation of $12.43M on NASDAQ/NYSE.

What is the P/E ratio of PHIO?

PHIO trades at a trailing price-to-earnings (P/E) ratio of -0.74. Its price-to-book (P/B) ratio is 0.62.

What is the return on equity (ROE) of PHIO?

PHIO has a return on equity (ROE) of -43.17%. Its return on capital employed (ROCE) is -45.76%.

Is PHIO a good stock to buy?

This page provides a data-driven analysis of PHIO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space